Rodrigo Teodoro Cartaxo

Highly accomplished postdoctoral researcher with expertise in investigating tumor stem cell migration in vitro and in vivo. Completed a rigorous 5-year training program at the University of Michigan. Demonstrated exceptional ability to secure internal and external funding through prestigious fellowships. Currently preparing findings for publication in a high-impact scientific journal within the next year.

Edwin Nieblas-Bedolla, M.D., M.P.H.

Department of Neurosurgery - University of Michigan, 2023, 2024

Kallen Schwark, MD/PhD Candidate

University of Michigan School of Medicine, 2021

Sunjong Ji, MD/PhD Candidate

University of Michigan School of Medicine/Cancer Biology Graduate School, 2020

Chase Thomas, B.S. Neuroscience

University of Michigan, 2019, 2020

Vishal John, B.S. Biopsychology, Cognition, and Neuroscience

University of Michigan, 2022, 2023

Michael Niculcea, B.S. Neuroscience

University of Michigan, 2023, 2024

Ariane Bocamino

Federal University of Alfenas - Brazil, 2009, 2010

Camila Paiva de Oliveira

Federal University of Alfenas - Brazil, 2009, 2010

Soraia Spozito

Federal University of Alfenas - Brazil, 2009, 2010

Reviewed Publications

1. Abrantes JL, Tornatore TF, Pelizzaro-Rocha KJ, de Jesus MB, Cartaxo RT, Milani R, Ferreira-

Halder CV. Crosstalk between kinases, phosphatases and miRNAs in cancer. Biochimie. 2014

Dec;107 Pt B:167-187, 2014, PMID 25230087

2. Miklja Z, Yadav VN, Cartaxo RT, Siada R, Thomas CC, Cummings JR, Mullan B, Stallard S, Paul

A, Bruzek AK, Wierzbicki K, Yang T, Garcia T, Wolfe I, Leonard M, Robertson PL, Garton HJ, Wahl

DR, Parmar H, Sarkaria JN, Kline C, Mueller S, Nicolaides T, Glasser C, Leary SE, Venneti S,

Kumar-Sinha C, Chinnaiyan AM, Mody R, Pai MP, Phoenix TN, Marini BL, Koschmann C.

Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma. J Clin Invest. 2020 Oct

1;130(10):5313-5325. 2020, PMID 32603316

3. Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M, Homan MJ, Marini BL, Kawakibi

AR, Ravindran R, Teodoro R, Yadav VN, Koschmann C. Targeting and therapeutic monitoring of

H3K27M-mutant glioma. Current Oncology Reports. 2020 Feb 6;22(2):19. 2020, PMID 32030483

4. Cantor E, Wierzbicki K, Tarapore RS, Ravi K, Thomas C, Cartaxo R, Yadav VN, Ravindran R,

Bruzek AK, Wadden J, John V, Babila CM, Cummings JR, Kawakibi AR, Ji S, Ramos J, Paul A,

Rodrigo Teodoro Cartaxo, Ph.D. September 17, 2024 Page 4 of 5

Walling D, Leonard M, Robertson P, Franson A, Mody R, Garton HJL, Venetti S, Odia Y, Kline C,

Vitanza NA, Khatua S, Mueller S, Allen JE, Gardner S, Koschmann C. Serial H3K27M cell-free

tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse

midline glioma. Neuro Oncology. 2022 Aug 1:24(8): 1366-1374, 2022, PMID 35137228

5. Schwark K, Messinger D, Cummings JR, Bradin J, Kawakibi A, Babila CM, Lyons S, Ji S, Cartaxo

RT, Kong S, Cantor E, Koschmann C, Yadav VN. Receptor tyrosine kinase (RTK) targeting in

pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine.

Front Oncol. 2022 Aug, 1:12:922928. , 2022, PMID 35978801

6. Venneti S, Kawakibi A, Ji S, Waszak S, Sweha S, Mota M, Pun M, Deogharkar A, Chung C, Tarapore

R, Ramage S, Chi A, Wen P, Arrillaga-Romany I, Batchelor T, Butowski N, Sumrall A,

Shonka N, Harrison R, de Groot J, Mehta M, Hall M, Daghistani D, Cloughesy T, Ellingson B,

Beccaria K, Varlet P, Kim M, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M,

Baum H, Burant C, Mottl S, Cartaxo R, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P,

Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins A, Wahl

D, Lyssiotis C, de la Nava D, Alonso M, Eze A, Spitzer J, Schmidt S, Duchatel R, Dun M, Cain J,

Jiang L, Stopka S, Baquer G, Regan M, Filbin M, Agar N, Zhao L, Kumar-Sinha L,Mody R,

Chinnaiyan A, Kurokawa R, Pratt D, Yadav V, Grill J, Kline C, Mueller, Resnick A, Nazarian J,

Allen J, Odia Y, Gardner S, Koschmann C*. Clinical efficacy of ONC201 in H3K27M-mutant

diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways.

Cancer Discovery. 2023 Nov; 13(11): 2370-2393, 2023, PMID37584601.

7. Holly J. Roberts, Sunjong Ji, Alberto Picca, Marc Sanson, Mekka Garcia, Matija Snuderl, Ulrich

Schüller, Thiébaud Picart, François Ducray, Adam L. Green, Yoshiko Nakano, Dominik Sturm, Zied

Abdullaev, Kenneth Aldape, Derek Dang, Chandan Kumar-Sinha, Yi-Mi Wu, Dan Robinson, Josh

N. Vo, Arul M. Chinnaiyan, Rodrigo Cartaxo, Santhosh A. Upadhyaya, Rajen Mody, Jason Chiang,

Suzanne Baker, David Solomon, Sriram Venneti, Drew Pratt, Sebastian M. Waszak & Carl

Koschmann. Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma

long-term survivors reveal a distinct group of tumors with MAPK pathway alterations. Acta

Neuropathol, 2023 Dec; 146(6): 849-852. 2023, PMID 37851269.

8. Koschmann,C, Al-Holou WN, Alonso MM, Anastas J, Bandopadhayay P, Barron T, Becher O,

Cartaxo R, Castro MG, Chung C, Clausen M, Dang D, Doherty R, Duchatel R, Dun M, Filbin M,

Franson A, Galban S, Moure MG, Garton H, Gowda P, Marques JG, Hawkins C, Heath A,

Hulleman E, Ji S, Jones C, Kilburn L, Kline C, Koldobskiy MA, Lim D, Lowenstein PR, Lu QR,

Lum J, Mack S, Magge S, Marini B, Martin D, Marupudi N, Messinger D, Mody R, Morgan M,

Mota M, Muraszko K, Mueller S, Natarajan SK, Nazarian J, Niculcea M, Nuechterlein N, Okada H,

Opipari V, Pai MP, Pal S, Peterson E, Phoenix T, Prensner JR, Pun M, Raju GP, Reitman ZJ,

Resnick A, Rogawski D, Saratsis A, Sbergio SG, Soud=weidane M, Stafford JM, Tzaridis T,

Venkataraman S, Vittorio O, Wadden J, Wahl D, Wechsler-Reya RJ, Yadav VN, Zhang X, Zhang Q,

Venneti S. A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell. 2024 Ja 8;

42(1): 1-5. 2024, PMID 38039965

9. Liu I, Cruzeiro GAV, Bjerke L, Rogers RF, Grabovska Y, Beck A, Mackay A, Barron T, Hack OA,

Quezada MA, Molinari V, Shaw ML, Perez-Somarriba M, Temelso S, Raynaud F, Ruddle R,

Panditharatna E, Englinger B, Mire HM, Jiang L, Nascimento A, LaBelle J, Haase R, Rozowski J,

Neyazi S, Baumgartner AC, Castellani S, Hoffman SE, Cameron A, Morrow M, Nguyen QD,

Pericoli G, Madlener S, Mayr L, Dorfer C, Geyeregger R, Rota C, Ricken G, Ligon KL,

Alexandrescu S, Cartaxo RT, Lau B, Uphadhyaya S, Koschmann C, Braun E, Danan-Gotthold M,

Rodrigo Teodoro Cartaxo, Ph.D. September 17, 2024 Page 5 of 5

Hu L, Siletti K, Sundström E, Hodge R, Lein E, Agnihotri S, Eisenstat DD, Stapleton S, King A, Bleil

C, Mastronuzzi A, Cole KA, Waanders AJ, Carcaboso AM, Schüller U, Hargrave D, Vinci M,

Carceller F, Haberler C, Slavc I, Linnarsson S, Gojo J, Monje M, Jones C*, Filbin MG*. GABAergic

neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma,

H3G34-mutant. 2024. Cancer Cell. In Press.

10. Rodrigo Cartaxo, Edwin Nieblas-Bedolla, Michael Niculcea, Madeline Miclea, Ruby Siada,

Kallen Schwark, Sunjong Ji, Ananya Gera, Robert Doherty, Stefanie Galban, Nicholas

Nuechterlein, Toshiro Hara, Jack Parent, Mariella Filbin, Carl Koschmann. Beta Integrins regulate

mitochondrially-mediated cell migration in H3K27M-diffuse midline glioma. In preparation (2024).